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Male rat liver undergoes a process of demasculinization during hepatic regeneration 
following partial hepatectomy. The possibility that antiandrogens might potentiate this 
demasculinization process and in so doing augment the hepatic regenerative response 
was investigated. Adult male Wistar rats were treated with the antiandrogenflutamide (2 
mg/rat/day or 5 mg/rat/day subcutaneously) or vehicle for three days prior to and daily 
after a 70% partial hepatectomy. At various times after hepatectomy, the liver remnants 
were removed and weighed. Rat'?s of DNA and polyamine synthesis were assessed by 
measuring thymidine kinase and ornithine decarboxylase activities, respectively. Hepatic 
estrogen receptor status and the activity of alcohol dehydrogenase, an androgen-sensitive 
protein, were measured. Prior to surgery, the administration of 5 mg/day flutamide 
reduced the hepatic cytosolic androgen receptor activity by 98% and hepatic cytosolic 
estrogen receptor content by 92% compared to that present in vehicle-treated controls. 
After hepatectomy, however, all differences in sex hormone receptor activity between the 
treatment groups were abolished. The rate of liver growth after partial hepatectomy in the 
three groups was identical. Moreover, hepatectomy-induced increases in ornithine 
decarboxylase activity and thymidine kinase activity were comparable. These data 
demonstrate that, although flutamide administration initially alters the sex hormone 
receptor status of the liver, these affects have no effect on the hepatic regenerative 
response following a partial hepatectomy. 
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The liver of mammals has been found to have a 
number of sexually dimorphic characteristics (1-
3). During regeneration following partial hepatec-
tomy, male rat liver is demasculinized in that 
many male-specific hepatic attributes disappear 
with the onset of the regenerative response (4). 
These changes include increases in hepatic estro-
gen receptor activity and serum estradiol levels 
and reductions in the level of serum testosterone 
and the hepatic content of androgen receptor, as 
well as reductions in the levels of several andro-
gen-responsive hepatic proteins. The importance 
of hepatic demasculinization during regeneration 
has not yet been determined. However, if hepatic 
demasculinization is an important aspect of the 
regeneration process, then the administration of 
an antiandrogenic drug might be expected to in-
tensity the demasculinization process and in so 
doing increase the rate of regeneration. 
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ANTIANDROGENS AND HEPATIC REGENERATION 
To investigate this hypothesis and the role of 
androgens in hepatic regeneration, the antiandrogen 
flutamide (a,a,a-trifluoro-2-methyl-4' -nitro-m-
propionotoluidide) was administered to adult male 
rats and the regenerative response following partial 
hepatectomy was examined. Flutamide is a nonste-
roidal anti androgen that has been shown to have 
little or no intrinsic androgenic activity (5, 6). 
Following a standard two-thirds hepatectomy, 
the rate of growth of the liver remnant was deter-
mined both in flutamide-treated animals and vehi-
cle-treated controls. In addition, the hepatic activ-
ities of thymidine kinase and ornithine 
decarboxylase were determined to assess the rates 
of DNA and polyamine synthesis, respectively. The 
activity of the estrogen receptors within the liver 
was determined to monitor the effect of treatment 
upon the estrogen receptor status of the liver during 
the regenerative process. Finally, the activity of 
hepatic alcohol dehydrogenase, an enzyme whose 
activity is repressed by androgens (7, 8), was as-
sayed. 
MATERIALS AND METHODS 
Animals and Supplies. Adult male inbred Wi star rats 
(200-350 g) were purchased from Harlan Sprague Dawley 
(Indianapolis, Indiana). The flutamide used was a gener-
ous gift of Schering Co. (Bloomfield, New Jersey). New 
England Nuclear (Boston, Massachusetts) was the source 
for the [14C]ornithine (57.6 mCi/mmol), [3H]estradiol (99 
Ci/mmo!) , [3H]RI881 (87 Ci/mmol), and unlabeled RI881 
utilized. Tritiated thymidine (5 Cilmmol) and ACS scin-
tillation fluid were purchased from Amersham (Arlington 
Heights, Illinois). Absolute ethanol and DEAE-cellulose 
paper were purchased from U.S. Industrial Chemicals 
Co. (Tuscola, Illinois) and BioRad (Richmond, Califor-
nia), respectively. Unlabeled ornithine, pyridoxal phos-
phate, Tris base, diethylstilbestrol, adenosine triphos-
phate, sodium molybdate, nicotinamide adenine 
dinucleotide, calf thymus DNA, and bovine serum albu-
min were purchased from Sigma Chemical Co (St. Louis, 
Missouri). All other chemicals were purchased from 
Fisher Chemical Co (Pittsburgh, Pennsylvania). 
Animal Treatment and Tissue Preparation. Male Wistar 
rats were assigned randomly to the various treatment 
groups. Animals in the flutamide-treated groups were 
given either 2 mg or 5 mg flutamide dissolved in a vehicle 
consisting of 0.2 ml peanut oil-acetone (9: l) subcutane-
ously beginning 72 hr prior to partial hepatectomy and 
every 24 hr thereafter until the time of sacrifice. Animals 
used as placebo controls received 0.2 ml of the peanut 
oil-acetone vehicle administered subcutaneously using 
the identical dosing schedule. A two-thirds partial hepa-
tectomy was performed under light ether anesthesia as 
described by Higgins and Anderson between 9:00 and 
12:00 AM (9). There was no difference in surgical mortality 
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between the treatment groups. The liver tissue removed 
at the time of hepatectomy served as the zero time control 
sample for each animal and was used to differentiate 
between the effects of drug treatment and hepatic resec-
tion for the various parameters assessed. 
At various times up to 72 hr after hepatectomy, animals 
from the vehicle control group and the two flutamide-
treated groups were anesthetized with ether and weighed. 
The liver remnant was removed, weighed, and homoge-
nized in 4 vol of ice-cold buffer consisting of 0.25 M 
sucrose, 1.5 mM EDTA, 10 mM mercaptoethanol and 10 
mM Tris HCl (pH 7.4) using a Brinkman Polytron homog-
enizer. Cytosol was prepared by centrifugation at 
103,000g for 1 hr at 4°C. All cytosolic enzyme assays 
were performed immediately after preparation of the 
cytosol. 
Hepatic nuclear samples were prepared as described by 
Porter et al. (10). Briefly, the livers were homogenized in 
3 vol of SMH buffer, consisting of 0.25 M sucrose, 3 mM 
MgCl2 in 10 mM HEPES (pH 7.4), with the addition of 
protease inhibitors (10 mM benzamidine, 0.15 mM leu-
peptin, 0.25 mM pepstatin A, and 0.5 mM phenylmethyl-
sulfonyl fluoride). Following centrifugation at 800g for 15 
min, the pellet was resuspended using a Dounce homog-
enizer in SMH buffer containing the protease inhibitors 
and 0.15% Triton X-l00. The samples were centrifuged at 
800g, and the final pellet was suspended in SMH buffer. 
Ornithine Decarboxylase Assay. Ornithine decarboxy-
lase activity was determined by measuring the 14C02 
released from labeled ornithine (11). In this assay, 0.4 ml 
cytosol was preincubated for 5 min at 37° C with a 
mixture containing 0.2 mM pyridoxal phosphate,S mM 
dithiothreitol, 1.5 mM I-ornithine in 10 mM Tris HCI (pH 
8.0). At the end of this period, 0.5 ILCi [1-14C]dl-ornithine 
was added to the mixture and 250 f.d of ethanolamine-
ethylene glycol (2: 1) was added to a center well to act as 
a CO2 trap. The assay flask was sealed and incubated at 
37° C for 1 hr. The reaction was terminated by the 
injection of 0.1 ml saturated trichloroacetic acid solution 
into the reaction mixture. After maintaining the reaction 
flask at 37° C for an additional hour, the CO2 trapping 
solution was removed and placed into a glass scintillation 
vial containing 10 ml ACS scintillation fluid. Radioactiv-
ity was measured in a Packard Tri-Carb 460 CD liquid 
scintillation system (Downers Grove, Illinois). 
Thymidine Kinase Assay. Thymidine kinase activity 
was determined by measuring the in vitro conversion of 
thymidine to thymidine phosphate (12). Cytosol (0.1 m!) 
was mixed with 850 ILl of incubation buffer, consisting of 
5 mM adenosine triphosphate, 3.6 mM MgCI2 in 50 mM 
Tris HCl (pH 8.0), and 50 ILl 1 ILM r3H]thymidine. The 
reaction was maintained at 37° C for 10 min and then 
terminated by immersion in boiling water for 2 min. After 
cooling in an ice bath, denatured protein was removed by 
centrifugation at 1500g for 5 min at 4° C. An aliquot (0.1 
ml) of the supernatant was then spotted on a 3.8 x 3.8-cm 
piece of DEAE-cellulose paper. The paper was washed 
twice with 1 mM ammonium formate for 5 min followed 
by distilled water for 3 min. Next, the paper was placed in 
a glass scintillation vial, and the radioactivity bound to 
the paper was eluted into solution by the addition of 1 ml 
0.1 M HCI-O.2 M KCI. After 15 min, 10 ml ACS scintil-
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lation fluid was added, and 3H present in the vial was 
determined. 
Sex Steroid Receptor Assays. Evidence indicating that 
estrogen receptors and, by inference androgen receptors, 
may actually be located in the nucleus only has been 
published (13, 14). Currently the traditional terms "cyto-
solic receptors" and "nuclear receptors" are considered 
to refer to ligand-free receptors loosely bound to nuclei 
and to occupied receptors tightly bound to nuclei, respec-
tively. Since the actual subcellular localization of the 
receptors was not pertinent to the present study, the 
traditional nomenclature has been employed. 
The activity of the cytosolic estrogen receptors was 
determined by measuring the specific binding of a satu-
rating concentration of [3H]estradiol (15). Hepatic cytosol 
prepared as described above was diluted 1: 1 with buffer 
consisting of 40 mM sodium molybdate, 1.5 mM EDT A, 
and 10 mM Tris HCI (pH 7.4) to stabilize the receptors. 
To measure total binding of the ligand, 200 j..ll of diluted 
cytosol was mixed with 25 j..ll 30 nM radioactive ligand 
and 25 j..ll ethanol. Nonspecific binding was measured in 
parallel assay in which the ethanol was replaced with 25 
j..ll 3 j..lM unlabeled DES dissolved in ethanol. Male-
specific estrogen binding protein binding was blocked by 
the inclusion of 200 j..lM 2-methoxyestriol in all cytosolic 
estrogen receptor assays (25). After 2 hr at 4° C, the 
incubation was terminated by the addition of 0.4 ml 1 % 
dextran-coated charcoal to each tube to remove unbound 
ligand (15). This suspension was then centrifuged for 5 
min at I500g at 4° C, and the supernatant was carefully 
transferred to a scintillation vial containing 8 ml ACS 
scintillation fluid. The radioactivity in the vial was mea-
sured. 
Nuclear estrogen receptor levels were measured by the 
method of Porter et al (10). Aliquots of the hepatic 
nuclear preparation were incubated in parallel at 30° C for 
90 min with 5 nM [3H]estradiol in the absence and 
presence of a 200-fold excess of unlabeled diethylstilbe-
strol to measure total and nonspecific binding, respec-
tively. At the end of the incubation period, unbound 
ligand was removed by four successive washings of the 
nuclei with ice-cold SMH buffer. After washing, absolute 
ethanol was added to the nuclear pellets and the tubes 
were maintained at 30° C for 30 min to facilitate the 
extraction of bound ligand. After centrifugation at I600g 
for 10 min, the supernatant was pipetted into scintillation 
vials and the radioactivity was measured. 
The cytosolic androgen receptor assay used was similar 
in design to that described above for the cytosolic estro-
gen receptor assay (4). Tritiated R1881, a synthetic an-
drogen, was used as a labeled ligand and unlabeled RI88I 
was used in the nonspecific binding assays. Triamcino-
lone acetonide (5 j..lM) was included in all androgen 
receptor assays to block binding of RI88I to glucocorti-
coid receptors. The only other difference between the two 
assay methods is that in the androgen receptor assay, the 
cytosol was incubated overnight at 4° C with the ligand 
rather than for 2 hr as in the cytosolic estrogen receptor 
assay. 
Alcohol Dehydrogenase Assay. Alcohol dehydrogenase 
activity was measured spectrophotometrically at 340 nm 
at ambient temperature by measuring NADH production 
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Cytololic Androgen Receptor Data 
Effect of Flutamide 
= Control E!mlI 2 mg!rat/day _ 5 mg!rat/day 
T",..., After Hepatectomy (rours) 
Fig 1. Effect of flutamide administration on hepatic cytosolic 
androgen receptor activity during hepatic regeneration. Receptor 
activities are reported as means ± SEM for 3-11 animals per 
group. **P < 0.01 vs vehicle-treated controls. 
in a I-ml reaction mixture consisting of cytosol, 2.8 mM 
nicotinamide adenine dinucleotide, and 18 mM ethanol in 
100 mM Tris HCl buffer (pH 7.2) (16). 
Miscellaneous Methods and Procedures. Protein concen-
trations were determined by the method of Lowry et al 
(17) with bovine serum albumin being used as the stan-
dard. DNA was measured fluorometrically (18) using calf 
thymus DNA as the standard. Statistical analysis of the 
data were performed using one-way ANOV A followed by 
Scheffe's test through the Abstat program on an IBM 
PC-XT. A P value of 0.05 or less was considered to 
represent a significant difference. All results are pre-
sented as mean values ± SEM. 
RESULTS 
Pretreatment with the higher dose flutamide prior 
to partial hepatectomy reduced the hepatic andro-
gen receptor content to barely detectable levels 
(Figure 1). In the liver of the control animals and the 
animals treated with the lower dose of flutamide, 
partial hepatectomy resulted in a rapid decrease in 
the cytosolic androgen receptor content at 24 hr, 
with a return toward normal levels at 72 hr follow-
ing surgery (Figure 1). 
The effects of flutamide treatment on changes in 
hepatic cytosolic estrogen receptor activity were 
similar in pattern to those observed for the andro-
gen receptor and are presented in Figure 2. The 
zero time hepatic cytosolic estrogen receptor activ-
ity of animals pretreated with the higher dose of 
flutamide was lower than that of the rats receiving 
either the lower dosage of the drug or the vehicle. 
Partial hepatectomy resulted in a reduction in the 
cytosolic activity of the estrogen receptors at 24 hr 
following surgery in the control animals. At 72 hr 
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Cytosolic Estrogen Receptor 
Effect of Flutamlde 
c:::::J Vehicle I!miIi!lI 2 mg/ratlday _ 5 mglratlday 
'0r--------------------, 
72 
Tme After l-iepatectomy (hours) 
Fig 2. Effect of ftutamide administration on hepatic cytosolic 
estrogen receptor activity during hepatic regeneration. Receptor 
activity is reported as mean femtomoles [3Hlestradiol bound per 
milligram cytosolic protein ± SEM for 3-11 animals per group. 
following hepatectomy, all three groups showed a 
reduced hepatic cytosolic content of estrogen re-
ceptors compared to that of the vehicle controls at 
time zero, and no subsequent difference in the 
content of estrogen receptor activity of the hepatic 
cytosol between groups was observed. As pre-
sented in Figure 3, the hepatic nuclear estrogen 
receptor activity in control animals was increased 
threefold at 72 hr, a time when serum estradiol 
levels have been shown to be maximally increased 
in animals subjected to partial hepatectomy (4). 
Notably, the estrogen receptor content of the liver 
of the 5 mg/day-treated animals, both prior to 
surgery and at all subsequent time points, was not 
different from that of the vehicle-treated controls 
(Figure 3). 
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Nuclear Estrogen Receptor Data 
Effect of Flutamlde 
= Control _ 5 mglrat/day 
Time After Hepatectomy (hours) 
Fig 3. Effect of ftutamide administration on hepatic nuclear 
estrogen receptor activity during hepatic regeneration. Data are 
presented as femtomoles [3Hlestradiol bound per 100 f.J..g DNA 
and are means ± SEM for 3-11 animals per group. 
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Alcohol Dehydrogenase Activity 
Effect of Flutamlde 
c:::.:l Control _ 5 mg/rat/day 
1Kr----------------------------------~ 
'2 
Time After Hepatectomy (hours) 
Fig 4. Effect of fiutamide administration on hepatic alcohol 
dehydrogenase activity during hepatic regeneration. Alcohol 
dehydrogenase activities are presented as milliunits activity per 
milligram cytosolic protein and are means ± SEM for 3-11 
animals per group. **P < 0.01 vs vehicle-treated controls. 
The effect of flutamide administration on the 
alcohol dehydrogenase activity of the liver during 
hepatic regeneration is shown in Figure 4. Neither 
partial hepatectomy nor treatment with ftutamide 
significantly altered the activity of the enzyme 
within the liver at any time point as compared to 
that of the vehicle-treated controls. 
Because ornithine decarboxylase is the rate-
limiting step in polyamine synthesis (19), the effect 
of ftutamide treatment on the induction of the 
activity of this enzyme was measured. The data 
presented in Figure 5 demonstrate that partial hep-
atectomy resulted in a IO-fold increase in the activ-
Ornithine Decarboxylase Activity 
Effect of Flutamide 
= Vehlcle _ 5 mg/rat/day 
~r-------------------------------------I 
I: 
Time After Hepatectomy 
Fig 5. Effect of ftutamide administration on the induction of 
hepatic ornithine decarboxylase activity after partial hepatec-
tomy. Ornithine decarboxylase (ODC) activities are presented as 
counts per minute 14C02 released per hour per milligram cyto-
solie protein and are means ± SEM for 3-11 animals per group. 
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Thymidine Kinase Activity 
Effect of Flutamide 
= Control IlIl!I!!iII 2 molratlday _ 5 molratlday 
nne After Hepatectomy (hours) 
Fig 6. Effect of flu tam ide administration on hepatic thymidine 
kinase activity during hepatic regeneration. Thymidine kinase 
activities are reported as disintegrations per minute thymidine 
phosphate produced per minute per milligram cytosolic protein 
and are means ± SEM for 3-11 animals per group. 
ity of this enzyme in hepatic cytosol. More impor-
tantly, it shows that flutamide administration had no 
effect on the hepatic activity of ornithine decarbox-
ylase either prior to or 6 hr after partial hepatec-
tomy, the time at which the enzyme is induced 
maximally in response to the hepatectomy stimulus 
(20). 
Hepatic regeneration necessarily involves an in-
crease in DNA synthesis within the liver, which 
requires an induction of hepatic thymidine kinase 
activity (12, 21). In the present study, the activity of 
thymidine kinase at the time of hepatectomy was 
comparable in the three sets of animals studied 
(Figure 6, time zero). Within 24 hr following partial 
hepatectomy, a significant induction of thymidine 
kinase activity within the liver was observed in all 
treatment groups. Moreover, the magnitude of the 
induction was similar for all groups at each of the 
time points investigated (Figure 6). 
The growth of the liver remnant after partial 
hepatectomy in control animals and the effect of the 
administration of the two dosages of flutamide on 
the rate of liver growth following two-thirds hepa-
tectomy is presented in Figure 7. An approximately 
twofold increase in the liver-body ratio in the 
control animals was observed between 6 and 72 hr 
after hepatectomy. There was no difference in the 
rate of hepatic growth between either group of 
animals treated with flutamide and the vehicle-
treated controls. 
To further ensure that the increases in liver 
weight measured during the course of the experi-
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Remnant/.ody R.atio 
Effect of Flutamide 
--c-- 2 moIrst/day -+- 5 mg/ratlday 
l~~--------------------------------~ 
~~ 02' 
I 0.18 0.1. -,--
0.1:2 
0 3. 40 00 
Tme After Hepatectomy O"lo<Isl 
Fig 7. Effect of flutamide administration on liver growth after 
partial hepatectomy. Male Wi star rats were treated for three 
days prior to and daily after a two-thirds partial hepatectomy. 
The data are presented as ratios of remnant weight to body 
weight at the time of sacrifice and are means ± SEM for 3-11 
animals per group. 
ments were not due either to hepatic glycogen 
accumulation, steatosis, or edema, the cytosolic 
protein concentration of the liver remnants was 
assessed (Figure 8). A transient, but probably not 
biologically important, difference (P < 0.05) be-
tween the 2 mg/day-treated animals compared to 
either the vehicle-treated controls or 5 mg/day drug-
treated animals was observed 36 hr but not 72 hr 
after surgery. 
DISCUSSION 
The liver of male rats loses many of its male-
specific characteristics during the regeneration that 
Cytosolic Protein Density 
Effect of Flutamide 
= Vehocle IIII!IIII 2 mglrat/dlly _ 5 mgI,atldlly 
Time After Hepatectomy It-oursl 
Fig 8. Effect of flutamide administration on hepatic cytosolic 
protein density during hepatic regeneration. Data are presented 
as milligrams cytosolic protein per gram wet weight liver and are 
means ± SEM for 3-11 animals per group. *p < 0.05 vs vehicle-
treated controls. 
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occurs following partial hepatectomy (4). It was 
therefore hypothesized that a disruption of the 
androgen-estrogen balance might alter the rate of 
hepatic growth occurring after a two-thirds hepatec-
tomy. In the present study the antiandrogen fluta-
mide was administered to rats for three days in an 
attempt to demasculinize the liver and thereby 
possibly increase the regenerative response after 
partial hepatectomy. The effect of this treatment on 
hepatic growth and several other aspects of hepatic 
regeneration was then assessed. 
Despite the fact that the doses of flutamide used 
here have been shown to alter the activity of certain 
sexually dimorphic hepatic enzymes (22) and did 
alter, at least at the higher dose used, androgen 
receptor levels prior to the partial hepatectomy 
stimulus for regeneration, in the present study rel-
atively few effects of flutamide treatment were 
observed either prior to or following partial hepa-
tectomy. Androgens have been shown previously to 
playa role in the growth of some cancers including 
hepatomas, and antiandrogen therapy has been use-
ful in the treatment of some tumors, particularly 
prostatic cancers (23). Moreover, recently the use 
of a synthetic androgen has been shown to enhance 
the long-term survival of alcoholics with alcoholic 
hepatitis in a large multicenter cooperative study 
within the Veterans Administration (24). 
Of the parameters investigated, the only statisti-
cally significant difference between the three groups 
studied prior to surgery was a 98% reduction in the 
hepatic cytosolic androgen receptor concentration 
in the 5 mg/day-treated animals, as expected, com-
pared to that present in the other two groups. This 
reduction in hepatic androgen receptor content was 
anticipated on the basis of several previous studies. 
First, flutamide treatment interferes with the 
expression, activity, and recycling of the androgen 
receptor in vivo. Such influences have been noted 
for the estrogen receptor when an antiestrogen has 
been used (25). The binding of flutamide and its 
active metabolite flutamide-OH (a,a,a-trifluoro-
2-methyl-4' -nitrolactotoluidide) to receptors in a 
variety of animal tissues had been investigated 
previously. The binding constant of flutamide for 
the androgen receptor varies, depending on the 
specific tissue being investigated, and ranges from 
0.01 to 0.2% of the binding of testosterone to 
androgen receptors in the same tissue (26). The 
affinity of its major metabolite, flutamide-OH (27), 
for the androgen receptor is also tissue-specific and 
has a 7- to 80-fold greater affinity for the receptor 
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compared to flutamide (26). Moreover, flutamide-
OH has been shown to be an effective competitor 
for hepatic androgen receptors in in vitro binding 
assays (P.K. Eagon, unpublished observations). 
Second, the administration of flutamide inhibits 
the hypothalamic-pituitary-gonadal axis and effects 
a reduction in testosterone synthesis. Testosterone 
is critical for the maintenance of androgen receptor 
activity, since castration of male rats was shown to 
reduce androgen receptor levels in the liver (28) and 
other tissues (29). Moreover, experiments in tissue 
culture of rat prostate and hamster ductus deferens 
cell lines (30) and human genital skin fibroblasts (31) 
have demonstrated that the cytosolic concentration 
of the androgen receptors is increased by the addi-
tion of androgens to the media. This up-regulation 
of the androgen receptor by its ligand is similar to 
the system hypothesized for the estrogen receptor 
(32). The antiandrogenic flutamide, or a metabolite 
thereof, could interfere either with gonadotropin 
secretion or androgen production and thereby re-
duce the level of androgen receptor within the liver 
(4). 
The rate at which the androgen receptor levels 
responded to hepatectomy in this and previous (4) 
studies was much more rapid than the changes in 
receptor activity observed after castration. In other 
studies, hepatic cytosolic androgen receptor levels 
had required 8-10 days after castration for a 50% 
reduction in androgen receptor activity to be evi-
dent (28). Thus, the rapid reduction in androgen 
receptor levels seen after partial hepatectomy may 
involve factors other than a reduction in serum 
testosterone levels. 
Further evidence that hepatic regeneration some-
how alters the sex hormone regulatory system of 
the liver was provided by the changes observed in 
the hepatic alcohol dehydrogenase activity follow-
ing partial hepatectomy. Previously, administration 
of androgens had been shown to reduce the activity 
of this enzyme in the liver by increasing the rate of 
degradation ofthe enzyme (33). Interestingly, in the 
present study the level of alcohol dehydrogenase 
activity in the control rats did not change during the 
course of the experiment. 
Based on these data, it appears that endogenous 
regulatory factors induced by hepatic regeneration 
are more potent than flutamide in the regulation of 
the sex hormone receptor activity and its expres-
sion within the liver. The mechanism(s) by which 
hepatic regeneration alters sex hormone receptor 
activity within the liver is as yet uncertain. One 
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possible explanation is that the changes in sex 
hormone metabolism caused by the hepatectomy 
and the obligate loss of hepatic metabolic capacity 
result in alterations in the amounts of sex hormones 
available for binding with or regulation of the recep-
tors at the level of the genome. 
Another hypothesis involves the putative growth-
stimulating factors released into the serum by re-
generating liver tissue (34, 35). These agents could 
return to the liver and indirectly alter sex hormone 
receptor regulation within the liver. No data have 
yet been published examining the influence of such 
factors on the hepatic sex steroid receptor system. 
Alternatively, these liver-derived serum factors 
could alter some other system that could then exert 
some influence on the androgen and estrogen recep-
tors. It is well established that modulation of the 
hypothalamic-pituitary axis alters the level of he-
patic estrogen- and androgen-sensitive proteins (36, 
37). The data obtained from the present studies do 
not allow a discrimination between these different 
possibilities. 
These data are consistent, however, with previ-
ous studies (22) in which flutamide administration 
has been shown to affect the balance between 
androgenic and estrogenic influences on the liver. 
The hypothesis that these effects would increase the 
rate of hepatic regeneration, however, was not 
substantiated, whether the results were expressed 
in terms of the rate of liver growth, induction of 
polyamine synthesis, or induction of DNA synthe-
sis. The observation that factors associated with the 
process of hepatic regeneration override the effects 
of the antiandrogen flutamide on androgen receptor 
activity suggests that androgens and their receptors 
play little or no apparent role in the process of 
hepatic regeneration. 
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